Harrer T, Schwab J, Struff W G, Schmitt M, Ficker J H, Rödl W, Parsch H, Kalden J R, Gramatzki M
Medizinische Klinik III, Universität Erlangen-Nürnberg, Germany.
Infection. 1998 Nov-Dec;26(6):368-74. doi: 10.1007/BF02770838.
In a pilot study the safety and therapeutic effects of an immunostimulatory intralymphatic treatment with natural human interleukin-2 (IL-2) in combination with zidovudine were evaluated in nine patients with AIDS. Therapy with IL-2 consisted of one subcutaneous injection of 0.1 microgram/kg IL-2, followed by four intralymphatic IL-2 infusions of 0.1 microgram/kg each within a period of up to 15 days. Enlargement of lymph nodes was seen in six and a transient increase of CD4 cells in five out of nine persons in association with the IL-2 therapy. An increase of HIV p24-antigenemia was observed only in the two patients in whom zidovudine dosage had to be reduced because of side effects. Moderate clinical side effects occurred in eight of the nine patients. Four patients developed zidovudine associated anemia. Six participants showed a favourable course of disease with survival of 25 to 54 months (median 30 months) despite a previous diagnosis of manifest AIDS before IL-2 therapy. This pilot study demonstrates that a combination therapy with intralymphatic IL-2 and zidovudine can induce positive immunomodulatory effects, even in the presence of manifest AIDS. Further studies should explore the tolerability and effects of a prolonged therapy with IL-2 in combination with a more potent antiviral drug combination therapy.
在一项初步研究中，对9名艾滋病患者评估了天然人白细胞介素-2（IL-2）与齐多夫定联合进行免疫刺激淋巴内治疗的安全性和治疗效果。IL-2治疗包括皮下注射一次0.1微克/千克IL-2，随后在长达15天的时间内进行4次淋巴内IL-2输注，每次0.1微克/千克。在接受IL-2治疗的9人中，有6人出现淋巴结肿大，5人CD4细胞短暂增加。仅在2名因副作用不得不减少齐多夫定剂量的患者中观察到HIV p24抗原血症增加。9名患者中有8名出现中度临床副作用。4名患者发生了与齐多夫定相关的贫血。6名参与者尽管在IL-2治疗前已被诊断为明显的艾滋病，但疾病进程良好，存活了25至54个月（中位数30个月）。这项初步研究表明，即使在存在明显艾滋病的情况下，淋巴内IL-2与齐多夫定联合治疗也可诱导积极的免疫调节作用。进一步的研究应探索延长IL-2治疗与更有效的抗病毒药物联合治疗的耐受性和效果。
